Impact of continuous glucose monitoring with diabetic education on glycemic variability and HbA1c

Mohan Varughese, Riju Mathew, Jessy Varghese, Cheryln Ann Chacko, Dona V. Augustine


Background: Continuous glucose monitoring (CGM) is an invasive technique which can be used in both outpatient and inpatient settings and can be used for assessing the glycemic variability among individuals with diabetes. It is an effective tool in diabetic management for evaluating the hypoglycemic, hyperglycemic and euglycemic events.

Methods: The study was both retrospective and prospective which was conducted at Believers Church Medical College Hospital, Thiruvalla after getting approval from the institutional ethical committee and patient consent was also taken. Patients with uncontrolled diabetes and those with suspicion of hypoglycaemia were taken from the patients attending the diabetic clinic from 26 July 2017. The study duration was from 26 July 2017 to 19 October 2019 (2 years).

Results: The study revealed the importance of CGM in the therapeutic management of diabetic patients by monitoring the individual patients and leading to an individualization of therapeutic regimen. It also helped to analyse the effect of each antidiabetic agent in the individual patients and thereby preventing the further occurrence of hypoglycemic and hyperglycemic stages in the individuals and will help to maintain a euglycemic stage in each individual and thus improving the patient’s quality of life.

Conclusions: Hence it is concluded from this study that CGM has an important role in the better therapeutic management in diabetic patients as it helps in individualisation of therapy based on each patient in a better glycaemic control leading to a euglycemic state resulting in statistically significant HbA1c reduction.


Continuous glucose monitoring, Diabetes mellitus, HbA1c, Type 2 diabetes mellitus

Full Text:



Glucose: continuous glucose monitoring. Available at: 11444-glucose-continuous-glucose-monitoring. Accessed on 8th January 2020.

Cengiz E, Sherr JL, Werinzimer SA, Tamborlane WV. New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Rev Med Dev. 2011;8(4):449-58.

Cheyne E, Kerr D. Making sense of diabetes: using a continuous glucose sensor in clinical practice. Diabet/metabol Res Rev. 2002;18 Suppl 1:S43-8.

Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-76.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. Diabet Care. 2010;33(1):17-22.

Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Diabetes Care. 2009;32(8):1378-83.

Wilson DM, Roy W, William V, Tamborlane, Mariya J. The accuracy of the freestyle navigator continuous glucose monitoring system in children with type 1 diabetes. Diabet Care. 2007;30(1):59-64.

Takahashi H, Iwahashi N, Kirigaya J, Kataoka S, Minamimoto Y, Gohbara M, et al. Glycaemic variability determined with a continuous glucose monitoring system can predict prognosis after acute coronary syndrome. Cardiovasc Diabetol. 2018;17:116.

Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7.

Lawton J, Blackburn M, Allen J, Campbell F, Elleri D, Leelarathna L, et al. Patients’ and caregivers’ experiences of using continuous glucose monitoring to support diabetes self-management: qualitative study. BMC Endocrine Dis. 2018;18(1):12.

Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805.

Unger J, Parkin CG. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. Postgrad Med. 2011;123:81-91.

Kenny C. When hypoglycemia is not obvious: diagnosing and treating under- recognized and undisclosed hypoglycemia. Prim Care Diabetes. 2014;8:3-11.

Jauch-Chara K, Schultes B. Sleep and the response to hypoglycemia. Best Pract Res Clin Endocrinol Metab. 2010;24:801-15.

Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemia in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabet Care. 2003;26:1153-7.

The diabetes research in children network (DirectNet) Study Group. Impact of exercise on overnight glycemic control in children with type 1 diabetes. J Pediatr. 2005;147:528-34.

Li W, Min R, Dong Y, Li Z, Sun Q, Li Y. Using continuous glucose monitoring to measure glucose variation of patients with type 2 diabetes: switching from premixed human insulin 70/30 to insulin lispro mix 75/25 or lispro mix 50/50 for 8 weeks. J Diab Res Clin Metabol. 2013;2:15.

Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.

Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818-28.

Scuffi C. Interstitium versus blood equilibrium in glucose concentration and its impact on subcutaneous continuous glucose monitoring systems. Eur Endocrinol. 2014;10(1):36-42.

Siegelaar SE, Holleman F, Hoekstra JBL, DeVries JH. Glucose variability; does it matter?. Endocr Rev. 2010;31:171-82.

Penckofer S, Quinn L, Byrn M. Does glycemic variability impact mood and quality of life?, Diabetes Technol Ther. 2012;14:303-10.

Klonoff DC, Technology to treat hyperglycemia in trauma. J Diabetes Sci Technol. 2007;1:151-2.

Rice MJ, Coursin DB, Continuous measurement of glucose: facts and challenges, Anesthesiol. 2012;116:199-204.

Wentholt IM, Vollebregt MA, Hart AA. Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabet Care. 2005;28:2871-6.

Adolfsson P. Selecting the appropriate continuous glucose monitoring system: a practical approach. Eur Endocrinol. 2018:24-29.

Cox DJ, Kovatchev BP, Julian DM, Gonder-Frederick LA, Polonsky WH, Schlundt DG, et al. Frequency of severe hypoglycemia in insulin dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab. 1994;79:1659-62.

Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabet Technol Ther. 2012;14:1008-12.

Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7.

Schnell O. Role of continuous glucose monitoring in clinical trials: recommendations on reporting; Diabet Technol Amp Therapeut. 2017;19:391-9.

Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18 (Suppl. 2):S3-S13.

Abbott: Free Style Libre Software 2017. Available at: Accessed on 28th February 2017.

Moser O, Mader JK, Tschakert G, Mueller A, Groeschl W, Pieber TR, et al. Accuracy of continuous glucose monitoring (CGM) during continuous and high-intensity interval exercise in patients with type 1 diabetes mellitus. Nutrient. 2016;8(8):489.

Nielsen JK, Gravholt CH, Djurhuus CB, Brandt D, Becker J, Heinemann L, et al. Continuous subcutaneous glucose monitoring shows a close correlation between mean glucose and time spent in hyperglycemia and hemoglobin A1c. J Diabet Sci Technol. 2007;1(6):857-63.

Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial. Diabet Care. 2016;39(8):1318-28.

Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabet Care. 2008;31(11):2086-91.

Detournay B, Halimi S, Robert J, Deschaseaux C, Dejager S. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. Vascular Health Risk Manag. 2015;11:417-25.

Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drug. 2008;68:2387-409.

Nauck M, Meininger G, Sheng DO, Terranella L, Stein PP, Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial. Diabet Obes Metabol. 2007;9(2):194-205.

Rusdiana MS, Amelia R. The effect of diabetes self-management education on Hba1c level and fasting blood sugar in type 2 diabetes mellitus patients in primary health care in Binjai City of North Sumatera, Indonesia. Open access Macedonian J Med Sci. 2018;6(4):715-8.